Novel and Emerging Drugs for Acute Lymphoblastic Leukemia

E.      Lech-Maranda; W.      Mlynarski

doi:10.2174/156800912800673275

Abstract

Over the past several decades the important progress has been made in the management of acute lymphoblastic leukemia (ALL), especially among children. However, in adult patients reported cure rates seldom exceeded 40%, despite the use of hematopoietic stem-cell transplantation in many cases. Conventional chemotherapy is toxic and ineffective. Therefore, new treatment options and risk-adapted therapies are needed to improve the outcome of ALL patients. This review is focused on new systemic treatment modalities, such as nucleoside analogues, purine synthetase inhibitors, monoclonal antibodies, tyrosine kinase inhibitors and other agents targeting molecular pathways that are aimed to benefit patients and improve the outcome of their treatment.

Keywords: Acute lymphoblastic leukemia, blinatumomab, DOT1L inhibitors, JAK/STAT inhibitors, monoclonal antibodies, mTOR inhibitors, NOTCH inhibitors, nucleoside analogues, tyrosine kinase inhibitors